Glucotrack Completes Second Long-Term Preclinical Study For Its Continuous Blood Glucose Monitor, Demonstrating Mean Absolute Relative Difference Of 4.7% At Day 90
Glucotrack Completes Second Long-Term Preclinical Study For Its Continuous Blood Glucose Monitor, Demonstrating Mean Absolute Relative Difference Of 4.7% At Day 90
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.